Download dihint21_group 1..500

BENPERIDOL
^ Bendamustine Hydrochloride see Bendamustine
^
^
^
^
^
^
^
^
^
^
^
involuntary movements. May be associated with depression and suicidal thoughts/behavior. Use extreme caution
in patients with psychotic disorders or patients receiving
phenothiazines or TCAs. May increase human growth
hormone levels. Use caution in patients with cardiovascular disease (MI, atrial, nodal, or ventricular arrhythmias);
initiate in a monitored setting. Use caution in patients with
ulcers, seizure disorders, and diabetes. Monitor IOP carefully in patients with wide-angle glaucoma. Use caution in
patients with renal or hepatic impairment; use is contraindicated in decompensated renal or hepatic disease. Do
not withdraw abruptly (may cause neuroleptic malignant
syndrome [NMS]). Patient must be instructed to resume
normal activities gradually (rapid mobilization may
increase risk of injury). Dopamine agonists used for Parkinson’s disease or restless legs syndrome have been
associated with compulsive behaviors and/or loss of
impulse control, which has manifested as pathological
gambling, libido increases (hypersexuality), and/or binge
eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to
the underlying disease, prior behaviors/addictions and/or
drug therapy. Dose reduction or discontinuation of therapy
has been reported to reverse these behaviors in some, but
not all cases. Risk for melanoma development is increased
in Parkinson’s disease patients; drug causation or factors
contributing to risk have not been established. Patients
should be monitored closely and periodic skin examinations should be performed.
on page 210
Benefiber® [OTC] see Wheat Dextrin on page 1932
Benefiber® Plus Calcium [OTC] see Wheat Dextrin
on page 1932
BeneFix® see Factor IX on page 734
Benemid [DSC] see Probenecid on page 1511
Benflumetol and Artemether see Artemether and Lumefantrine on page 156
BenGay® [OTC] see Methyl Salicylate and Menthol
on page 1191
Benicar® see Olmesartan on page 1323
Benicar HCT® see Olmesartan and Hydrochlorothiazide
on page 1325
Benlysta® see Belimumab on page 206
Benlysta™ (Can) see Belimumab on page 206
Benoxinate Hydrochloride and Fluorescein Sodium
see Fluorescein and Benoxinate on page 783
Benperidol [INT]
(ben PER i dole)
International Brand Names Anquil (GB, IE); Benperidolneuraxpharm (DE); Concilium (AR); Frenactil (BE, LU, NL);
Glianimon (DE, GR)
Pharmacologic Category Antipsychotic Agent, Typical,
Phenothiazine
Reported Use Treatment of psychotic conditions including
control of deviant antisocial sexual behavior
Dosage Range Adults: Oral: 0.25-1.5 mg/day in divided
doses
Product Availability Product available in various countries; not currently available in the U.S.
Patients must be cautioned about performing tasks which
require mental alertness. [Canadian Boxed Warning]:
Patients have reported falling asleep while engaging in
activities of daily living and sometimes without significant
warning signs. Monitor for daytime somnolence or preexisting sleep disorder; discontinue if significant daytime
sleepiness or episodes of falling asleep occur. Use with
caution in patients receiving other CNS depressants or
psychoactive agents; effects with other sedative drugs or
ethanol may be potentiated.
Dosage Forms
Tablet: 0.25 mg
Benserazide and Levodopa [CAN/INT]
Distribute dietary protein throughout the day to avoid
fluctuations of levodopa absorption. Use with caution in
the elderly; may be more sensitive to CNS effects of
levodopa.
Adverse Reactions Frequency not defined.
Cardiovascular: Arrhythmias, chest pain, edema, ECG
changes (nonspecific), flushing, hypertension, orthostatic
hypotension, pallor, phlebitis
Central nervous system: Agitation, anxiety, ataxia, bruxism, confusion, delusions, dementia, depression, euphoria, faintness, fatigue, fever, gait abnormalities,
hallucinations (mostly visual), headache, impulse control
symptoms (including pathological gambling), insomnia,
lethargy, malaise, neuroleptic malignant-like syndrome,
nightmares, oculogyric crisis, on-off phenomena, paranoid ideation, psychotic episodes, sedation, seizures,
somnolence, suicidal tendencies/behavior, temporal disorientation, trismus
Dermatological: Alopecia, pruritus, rash
Endocrine & metabolic: Libido increased, protein-bound
iodine increased, uric acid increased
Gastrointestinal: Abdominal distress or pain, anorexia,
burning sensation on tongue, constipation, diarrhea,
duodenal ulcer, dysphagia, epigastric pain, eructation,
flatulence, GI bleeding, nausea, sialorrhea, taste alterations, vomiting, weight gain/loss, xerostomia
Genitourinary: Discoloration of urine, hematuria, nocturia,
urinary frequency, urinary retention or incontinence
Hematologic: Agranulocytosis, hemolytic anemia (rare),
leukopenia (transient), Positive Coombs' test, thrombocytopenia
Hepatic: Alkaline phosphatase increased, bilirubin
increased, LDH increased, transaminases increased
(ben SER a zide & lee voe DOE pa)
Brand Names: Canada Prolopa®
Index Terms Levodopa and Benserazide
Pharmacologic Category Anti-Parkinson's Agent, Dopamine Agonist
Use Treatment of Parkinson's disease (except druginduced Parkinsonism)
Pregnancy Considerations Teratogenic effects have
been observed with levodopa in animal reproduction studies; use is contraindicated in pregnant women and women
of childbearing age without proper contraception.
Lactation Excretion in breast milk unknown/not recommended
Contraindications Hypersensitivity to benserazide, levodopa, sympathomimetics, or any component of the formulation; use with or within 14 days of MAO inhibitors;
patients with clinical laboratory evidence of uncompensated cardiovascular, endocrine, renal, hepatic, hematologic, or pulmonary disease; patients with decompensated
endocrine, renal, hepatic, cardiac disorders, psychiatric
disorders, narrow-angle glaucoma, or closed-angle glaucoma; patients <25 years of age (due to possibility of
skeletal abnormalities from benserazide); pregnancy or
use in women of childbearing potential without adequate
contraception
Warnings/Precautions If patient is already receiving levodopa, discontinue levodopa at least 12 hours before
starting benserazide/levodopa and begin at 15% of previous amount of levodopa. Not indicated in management of
intention tremor, Huntington's chorea, or drug-induced
extrapyramidal symptoms. Administer in careful increments and observe closely for development of abnormal
212